Estamos realizando la búsqueda. Por favor, espere...
1575
37
170
28821
4394
2595
347
299
Abstract: The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein?Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica?SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica?SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.
Fuente: Clinical and Translational Oncology, 2022, 24, 1890-1902
Editorial: Springer-Verlag Italia
Fecha de publicación: 23/06/2022
Tipo de publicación: Artículo de Revista
DOI: 10.1007/s12094-022-02856-1
ISSN: 1699-048X,1699-3055
Url de la publicación: https://doi.org/10.1007/s12094-022-02856-1
Leer publicación
TRIGO, JOSÉ
GARCÍA-COSÍO, MÓNICA
MARIA DE LA ALMUDENA GARCIA CASTAÑO
GOMÀ, MONTSERRAT
MESIA-NIN, RICARD
RUIZ-BRAVO, ELENA
SORIA-RIVAS, AINARA
CASTILLO, PAOLA
BRAÑA GARCÍA, IRENE
ALBEROLA-FERRANTI, MARGARITA
Volver